Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Orchard Therapeutics plc | ortx-ex312_7.htm |
| EX-31.1 - EX-31.1 - Orchard Therapeutics plc | ortx-ex311_6.htm |
| 10-Q - 10-Q - Orchard Therapeutics plc | ortx-10q_20200930.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Orchard Therapeutics plc(the “Company”) on Form 10-Q for the period ending September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers does hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: November 3, 2020 |
By: |
/s/ Bobby Gaspar |
|
|
|
Bobby Gaspar |
|
|
|
Chief Executive Officer (Principal Executive Officer) |
|
Date: November 3, 2020 |
By: |
/s/ Frank E. Thomas |
|
|
|
Frank E. Thomas |
|
|
|
President and Chief Operating Officer (Principal Financial Officer and Principal Accounting Officer) |